Beneficial effects of high doses of growth hormone in the introduction and optimization of medical treatment in decompensated congestive heart failure.

[1]  P. Kelly,et al.  GH prevents apoptosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism. , 2004, The Journal of endocrinology.

[2]  A. Angelini,et al.  Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure. , 2004, American journal of physiology. Cell physiology.

[3]  R. Napoli,et al.  Growth hormone, acromegaly, and heart failure: an intricate triangulation , 2003, Clinical endocrinology.

[4]  Michael Georgiadis,et al.  Effects of growth hormone on circulating cytokine network, and left ventricular contractile performance and geometry in patients with idiopathic dilated cardiomyopathy. , 2003, European heart journal.

[5]  Guido Iaccarino,et al.  Growth hormone prolongs survival in experimental postinfarction heart failure. , 2003, Journal of the American College of Cardiology.

[6]  S. Anker,et al.  Growth hormone resistance in chronic heart failure and its therapeutic implications. , 2003, Journal of cardiac failure.

[7]  G. Heller,et al.  A 24‐Hour Comparison of Serum Growth Hormone Concentrations in Patients with Heart Failure versus Healthy Controls , 2003, Pharmacotherapy.

[8]  M. Anastasiou-Nana,et al.  Hormonal profile in patients with congestive heart failure. , 2003, International journal of cardiology.

[9]  F. Peale,et al.  Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. , 2002, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[10]  S. Adamopoulos,et al.  Growth hormone administration reduces circulating proinflammatory cytokines and soluble Fas/soluble Fas ligand system in patients with chronic heart failure secondary to idiopathic dilated cardiomyopathy. , 2002, American heart journal.

[11]  J. Cleland,et al.  Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial , 2002, The Lancet.

[12]  G. Schuler,et al.  Reduction of insulin-like growth factor-I expression in the skeletal muscle of noncachectic patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[13]  S. Anker,et al.  From tissue wasting to cachexia: changes in peripheral blood flow and skeletal musculature , 2002 .

[14]  D. Sane,et al.  Growth hormone, insulin-like growth factor-1 and the aging cardiovascular system. , 2002, Cardiovascular research.

[15]  James B. Young.  Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial , 2002 .

[16]  L. Stevenson,et al.  Medical management of advanced heart failure. , 2002, JAMA.

[17]  R. Napoli,et al.  Growth hormone corrects vascular dysfunction in patients with chronic heart failure. , 2002, Journal of the American College of Cardiology.

[18]  R. Dietz,et al.  Cardiac and Renal Effects of Growth Hormone in Volume Overload–Induced Heart Failure: Role of NO , 2002, Hypertension.

[19]  P. Poole‐Wilson,et al.  Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone. , 2001, Journal of the American College of Cardiology.

[20]  R. Dietz,et al.  Growth Hormone Treatment in Dilated Cardiomyopathy , 2001, Journal of cardiac surgery.

[21]  F. Spinale,et al.  Treatment With a Growth Hormone Secretagogue in a Model of Developing Heart Failure: Effects on Ventricular and Myocyte Function , 2001, Circulation.

[22]  F. Spinale,et al.  Effects of growth hormone supplementation on left ventricular morphology and myocyte function with the development of congestive heart failure. , 1999, Circulation.

[23]  N R Webster,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.

[24]  L. Saccá.  Growth hormone therapy for heart failure: swimming against the stream. , 1999, Journal of cardiac failure.

[25]  M. Volterrani,et al.  Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. , 1999, American heart journal.

[26]  B. Lorell,et al.  Treatment with growth hormone enhances contractile reserve and intracellular calcium transients in myocytes from rats with postinfarction heart failure. , 1999, Circulation.

[27]  M. Lomsky,et al.  A placebo-controlled study of growth hormone in patients with congestive heart failure. , 1998, European heart journal.

[28]  P. Poole‐Wilson,et al.  Deficient insulin-like growth factor I in chronic heart failure predicts altered body composition, anabolic deficiency, cytokine and neurohormonal activation. , 1998, Journal of the American College of Cardiology.

[29]  M. Elam,et al.  Intense sympathetic nerve activity in adults with hypopituitarism and untreated growth hormone deficiency. , 1998, The Journal of clinical endocrinology and metabolism.

[30]  P. Poole‐Wilson,et al.  Randomised, double-blind, placebo-controlled trial of human recombinant growth hormone in patients with chronic heart failure due to dilated cardiomyopathy , 1998, The Lancet.

[31]  P. Ponikowski,et al.  Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. , 1997, Circulation.

[32]  P. Ponikowski,et al.  Wasting as independent risk factor for mortality in chronic heart failure , 1997, The Lancet.

[33]  D. Green,et al.  Treatment of end-stage cardiac failure with growth hormone , 1997, The Lancet.

[34]  M. Volterrani,et al.  Haemodynamic effects of intravenous growth hormone in congestive heart failure , 1997, The Lancet.

[35]  C. Malbon,et al.  Insulin-like Growth Factor Receptor-1 Stimulates Phosphorylation of the β2-Adrenergic Receptor in Vivo on Sites Distinct from Those Phosphorylated in Response to Insulin* , 1996, The Journal of Biological Chemistry.

[36]  M. Tewari,et al.  Activation of the insulin‐like growth factor‐I receptor inhibits tumor necrosis factor‐induced cell death , 1996, Journal of cellular physiology.

[37]  B. Biondi,et al.  A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. , 1996, The New England journal of medicine.

[38]  M. Russo,et al.  Reversible dilated cardiomyopathy due to growth hormone deficiency. , 1992, Chest.